Sutro Biopharma (STRO) Peer Comparison

$20.45

$-0.86 (-4.04%)

As on 28-Aug-2026 16:00EDT

Market cap

$339 Mln

Revenue (TTM)

$46 Mln

P/E Ratio

--

P/B Ratio

2.1

Div. Yield

0 %

Edit

	Sutro Biopharma (STRO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Market cap ($ Mln)	339	16,765	16,261	13,492	11,994
Revenue ($ Mln)	46	2,782	1,054	2,436	670
Net Profit ($ Mln)	-180.64	491.50	755.85	860.62	-319.95
Net Margin (%)	-395.25	17.67	71.69	35.33	-47.79
RoE (%)	--	110.09	--	42.98	-71.14
Price to Earnings	--	35.25	19.00	17.40	--
Price-To-Book	2.11	39.29	9.76	7.42	26.87

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Sutro Biopharma (STRO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Operating Revenue	45.70	2,782.29	1,054.37	2,435.92	669.50
Cost of Revenue	4.80	1,982.07	103.47	85.67	19.14
Gross Profit	95.16	760.62	588.53	2,236.43	829.45
Operating Expenses	186.04	216.81	841.45	1,378.74	895.93
Operating Profit (EBIT)	-141.62	583.40	109.45	971.51	-226.44
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-180.73	598.92	101.11	1,035.47	-252.08
Provision for Tax	-0.10	107.42	-654.74	174.84	20.05
Profit after Tax (Net Income)	-180.64	491.50	755.85	860.62	-319.95
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Sutro Biopharma (STRO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Shareholder's Funds	-103.32	433.86	1,435.90	1,843.76	465.53
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Non-Current Liabilities	244.88	187.89	384.48	288.55	1,362.63
Current Liabilities	52.90	1,435.43	464.70	361.93	283.35
Total Liabilities	173.83	1,975.47	1,302.02	2,844.42	1,385.30

Assets ($ Mln)

	Sutro Biopharma (STRO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Non-Current Assets	18.82	1,006.90	895.24	1,243.41	440.60
Current Assets	175.65	1,050.29	1,389.84	1,250.82	1,671.41
Total Assets	173.83	1,975.47	1,302.02	2,844.42	1,385.30
Total Debt*	10.78	120.10	449.89	165.93	864.07
Net Current Assets	0.00	-385.14	0.00	888.90	1,388.07

Cashflow ($ Mln)

	Sutro Biopharma (STRO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Cash From Operating Activities	-177.23	713.22	51.77	884.27	179.55
Cash Flow from Investing Activities	45.01	-31.14	-8.15	350.44	-129.29
Cash from Financing Activities	0.04	-860.39	34.89	-969.59	74.01
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Sutro Biopharma (STRO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
ROCE (%)	779.58	53.56	-30.01	32.82	-0.17
ROE (%)	435.02	110.09	163.18	42.98	-71.14
ROA (%)	-51.12	15.64	26.53	29.32	-16.12
EBIT Margin (%)	-307.79	21.13	5.73	31.04	-0.77
Net Margin (%)	-395.25	17.67	71.69	35.33	-47.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Sutro Biopharma (STRO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Revenue Growth (%)	-56.25	24.67	114.85	9.23	12.22
EBIT Growth (%)	6.58	18.70	136.39	-3.99	93.17
Net Profit Growth (%)	13.45	17.50	378.76	42.89	-115.58
EPS Growth (%)	30.97	26.84	353.27	50.42	-73.87
Book Value Growth (%)	-64.22	164.02	816.12	-0.70	-13.57

Valuation Ratios

	Sutro Biopharma (STRO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Price / Earnings	-0.52	36.06	-59.76	15.79	-2,869.63
Price / Book Value	2.11	39.29	9.76	7.42	26.87
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	-1.58	27.43	211.41	12.12	-81.53
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Sutro Biopharma (STRO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debt to Equity	0.00	0.00	0.00	0.00	1.77
Short term debt to equity ratio	-0.06	0.00	0.05	0.00	0.09
Current Ratio	3.32	0.73	2.99	3.46	5.90
Quick Ratio	3.32	0.73	2.32	3.38	5.90
Interest Coverage	-3.51	--	1.62	--	-1.72

Operating Efficiency Ratios

	Sutro Biopharma (STRO)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debtors to sales (%)	12.68	15.88	21.25	13.74	1.28
Asset Turnover	0.13	0.89	0.37	0.83	0.34
Receivable days	22.44	50.42	85.52	43.48	1.50
Inventory Days	--	--	1,056.70	96.17	--
Payable days	449.83	6.26	331.01	147.97	221.81
Cash Conversion Cycle	--	--	811.21	-8.32	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly